Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Expert scientist and drug development leader to scale high-impact, AI-enabled quantitative systems pharmacology team to accelerate medicines to patients

RADNOR, PA – 2026 年 4 月 8 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced that Dr. Britta Wagenhuber has joined the company as Head of Quantitative Systems Pharmacology (QSP) Consultancy.

Dr. Wagenhuber brings more than 14 years of experience in mechanistic model-informed drug development (MIDD), with deep expertise in quantitative systems pharmacology, pharmacometrics, physiologically based pharmacokinetic (PBPK) modeling, clinical trial simulation, and AI/ML-driven data analytics. In her new role, she will help further scale Certara’s QSP capabilities, enabling clients to leverage greater mechanistic understanding of drug action and biology to inform critical decision-making and accelerate the delivery of novel medicines to patients.

Dr. Wagenhuber joins Certara from Sanofi, where she held senior leadership roles in Quantitative Systems Pharmacology and Translational Disease Modeling. She led multidisciplinary teams supporting discovery and development decision-making across a wide range of therapeutic areas, including immunology and inflammation, diabetes and metabolism, cardiovascular disease, oncology, and vaccines.

“Britta’s appointment reflects our continued investment in delivering scientific excellence and client impact,” said Piet van der Graaf, Senior Vice President and Head of QSP at Certara. “She brings a unique combination of scientific expertise, industry leadership, and firsthand understanding of the client experience. As we continue to build the largest and most experienced QSP team in the industry, Britta will play a critical role in democratizing AI-enabled model-informed evidence generation for decision making.”

Dr. Wagenhuber holds a Ph.D. in Computational Life Sciences from the University of Lübeck and has authored numerous peer-reviewed publications and patents in systems pharmacology and metabolic modeling.

“I am excited to join Certara at such a pivotal time for the industry,” said Dr. Wagenhuber. “There is tremendous opportunity to scale AI-enabled, mechanistic modeling approaches to improve decision-making and bring innovative medicines to patients faster. I look forward to working with Certara’s world-class QSP team and partnering with clients to increase confidence in development decisions and unlock the full value of quantitative systems pharmacology.”

Certara has the largest team of QSP scientists in the industry, dedicated to delivering high-impact science, exceptional client experiences, and innovative solutions that accelerate drug development.

To learn more about Certara’s Quantitative Systems Pharmacology services, visit:
https://www.certara.com/services/quantitative-systems-pharmacology/

关于Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. 其客户包括超 2,600 家生物制药公司、学术机构和来自 70 个国家的监管机构。Learn more at certara.com